|
|
|
Evaluation of a Novel Approach for the Measurement of RNA Quality
LGC Limited
The potential medical applications of microarrays have generated much interest, within the biomedical community. Numerous potential sources of variation have raised concerns regarding assay consistency and data quality. Previous studies have highlighted RNA integrity as having a major effect on data quality. We describe here a comparison of the performance characteristics of the Agilent (Bioanalyser) and Lab901 (Screen Tape System) platforms, and their capacity to determine sample RNA integrity.
|
Intended transcriptional gene silencing with siRNA to the human Vascular Endothelial Growth Factor (VEGF) promoter results in VEGF repression through sequence-specific off-targeting
School of Biotechnology & Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia; Eli Lilly Pty. Ltd., West Ryde, NSW, Australia
SiRNA designed to target the human VEGF gene promoter revealed a putative candidate for transcriptional gene silencing. However, mutation or deletion of the target site demonstrated that the observed VEGF knockdown was the result of a sequence-specific off-target effect. Bioinformatic and microarray analyses of genes implicated in VEGF transcriptional control followed by knockdown and Western blotting experiments presented one candidate, GRB2, as an unintended target of the VEGF promoter-specifi
|
A Web Interface for Automatic Microarray Analysis
Nottingham University
DNA-Microarray technology provides a diagnostic tool for studying cancer and genetic diseases, allowing the experimenter to identify disease related genes and predict the tumour type for new cell samples. However, the statistical analysis of microarray data is a time-consuming and error-prone process. To address this problem we have developed a web interface for automatic DNA-microarray analysis, ArrayMining.net, which guides the user through the analysis process and performs automatic parameter
|
| |
|
|
Target Discovery World Congress, South San Francisco, CA, USA
04 August 2009 - 05 August 2009
Target Discovery World Congress will be a meeting focusing on the research looking to find new potential drugs for development. The topics will include presentations on the latest in screening platforms and new methods such as those in High Content and Label-Free Screening and will also focus on the work being done looking for new drug targets in some of the major protein families including Ion Channels, GPCRs, Protein Kinases, Nuclear Receptors and the Ubiquitin Pathway.
|
Molecular Diagnostics World Congress, South San Franscisco, CA, USA
06 August 2009 - 07 August 2009
Welcome to the 2nd Molecular Diagnostics World Congress, this year's event will take place at the South San Francisco Conference Center.
|
Microarray World Congress, South San Francisco, CA, USA
06 August 2009 - 07 August 2009
Welcome to the Microarray World Congress where you will hear about the latest developments and applications in the rapidly expanding field of microarrays.
|
Epigenetics World Congress, Berlin, Germany
17 September 2009 - 18 September 2009
Welcome to the inaugural Epigenetics World Congress. This year's event will take place in the exciting city of Berlin.
|
|
| |
|
|
|
|
|
MicroRNA Regulation in 5-FU Treated Pancreatic Cancer Cells
Bao-Ling Adam, Assistant Professor, Center for Biotechnology and Genomic Medicine, Medical College of Georgia, speaking at the RNAi World Congress 2008
|
|
Molecular Correlates of Prostate Cancer Subtypes
Sunita Setlur, Post Doctoral Fellow, Brigham and Women’s Hospital, Harvard Medical School, speaking at the RNAi World Congress 2008
|
|
Epigenetics, MicroRNA, and RNAi Therapeutics: Market Snapshots
Enal Razvi, Biotechnology Analyst, Select Biosciences speaking at the RNAi World Congress 2008
|
|
|
|
RNAi Therapeutics 2008
Published November 2007
This is the latest RNAi-based Therapeutics Market Report from Select Biosciences. This report presents an up-to-date thorough analysis of the RNAi therapeutics landscape based upon our continuing coverage of this dynamic marketplace. This report presents an exhaustive analysis of all the therapeutics areas where research efforts using RNAi-based therapeutics are being focused: From Research/Pre-Clinical through Phase III Clinical Trials. Select Biosciences proprietary market survey addresses dru
|
Epigenetics and MicroRNA Diagnostics/Therapeutics 2008 Market Report
Published May 2008
Epigenetics is undergoing a massive industry expansion and this report focuses in on the science, market, and therapeutics trends in this emerging area. Select Biosciences proprietary market analyses addressed the qualitative and quantitative trends in the epigenetics marketplace focusing on the technology trends, market trends, and therapeutics space.
|
|
|
|
FabRICATOR® - perfect F(ab?)2 fragments in minutes
Genovis
Fab and F(ab?)2 antibody fragments are used in applications or assays where the presence of the Fc region may cause problems. If antibodies are used for staining of a specific target in tissues like spleen, lymph or in peripheral blood preparations, cells with Fc receptors (macrophages, monocytes, natural killer cells and B lymphocytes) can bind to the Fc region of the antibody and cause a background staining in areas that do not contain any antigen. Fab and F(ab?)2 fragments are also desirable
|
Knockdown of BACE-1, an Alzheimer’s Disease Drug Target, with NIMT®FeOfection|PURPLE
Genovis
Small interfering RNA (siRNA) has become a widely used tool over the past years in the study of gene function and shows potential for drug development. However, in vivo siRNA delivery is the major obstacle that has to be overcome. The commercial cationic lipid based transfection reagents are toxic to the cells and are not compatible for in vivo application.
|
|